Abstract
Translocations are key oncogenic events, and many rearrangements are characteristic for a specific malignancy. We present here a case of phenotypic precursor-B acute lymphoblastic leukemia (ALL), subsequently found to have both MYC and MLL translocations. Owing to the potential prognostic impact of these translocations, a novel treatment strategy was applied which merged precursor-B ALL, Burkitt-ALL, and "MLL-adapted" rationales. With the advent of expanding diagnostic panels and molecular therapeutic options, use of such adapted therapies for individualized treatment will undoubtedly continue to increase as we move toward pharmacogenomic-based approaches.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Child, Preschool
-
Cyclophosphamide / administration & dosage
-
Cytarabine / administration & dosage
-
Doxorubicin / administration & dosage
-
Flow Cytometry
-
Histone-Lysine N-Methyltransferase
-
Humans
-
Male
-
Methotrexate / administration & dosage
-
Myeloid-Lymphoid Leukemia Protein / genetics*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics*
-
Prednisone / administration & dosage
-
Proto-Oncogene Proteins c-myc / genetics*
-
Translocation, Genetic*
-
Vincristine / administration & dosage
Substances
-
KMT2A protein, human
-
MYC protein, human
-
Proto-Oncogene Proteins c-myc
-
Cytarabine
-
Myeloid-Lymphoid Leukemia Protein
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Histone-Lysine N-Methyltransferase
-
Prednisone
-
Methotrexate